Gilead Sciences’ vice president and general manager for Italy, Valentino Confalone, outlines the company’s tumultuous pandemic journey in one of the first global epicentres; the role that Italy played in the early studies of remdesivir as a treatment against severe…
Writing in the January edition of DIA’s Global Forum magazine, Julia Chan, David Liew, Jana Stojanova, and Chris McMaster of Austin Health, Melbourne and St. Vincent’s Hospital Sydney outline how…
All about marketing, manufacturing, packaging & labeling, advertising in Ireland. Prepared in association with Mason Hayes & Curran, a leading law firm in Ireland, this is an extract from The…
Saudi Arabia – by many measures the cultural, social, and economic centre of the Arab and Islamic worlds – is currently undergoing a once-in-a-lifetime transformation. The ‘Vision 2030’ transformation plan…
One of the enduring conundrums around ground-breaking and potentially paradigm-shifting treatments such as CAR-T is the ever-thorny question of how fast to move them to market when the promise seems…
Over two years since the first cases of COVID-19, the world is still coming to terms with the virus. While vaccines have been developed and rolled out in record time…
Bernie Zeiher, chief medical officer (CMO) of Astellas explains why the ‘patient-defined value’ of medicines is crucial to developing therapies that truly address patients’ unmet medical needs. Zeiher outlines some…
Speaking exclusively to PharmaBoardroom, Jan van de Winkel highlights the tremendous progress that European biotech success story Genmab has made over the past six years, how its partnership model is evolving, Denmark’s continuing relevance to the company, and Genmab’s value proposition for the next generation of talent. Genmab has strong, focused investment into its pipeline and capabilities and is…
Speaking exclusively to PharmaBoardroom, Lundbeck’s global CEO Deborah Dunsire describes the progress in the strategy she put in place to…
Ercin Kugu, CSL Behring’s general manager for Turkey and Israel, highlights the rare disease company’s footprint in Turkey, explains the…
David H. Crean summarizes the recent 40th annual J.P. Morgan Healthcare Conference 2022 that was held in a virtual format. Crean underlines the importance of the Conference for establishing the tone…
As complex cutting-edge therapies come online, industry sponsors are increasingly looking to engage with patients, caregivers, and advocacy groups earlier and more broadly in the drug development process to better…
Susan L. Lang outlines how pharma companies can navigate drug formulary exclusions, numbers of which have been rising in recent years, and ensure that newly FDA approved medicines can make…
Based on IQVIA’s pharma market rankings for 2020, we give a rundown of the global top 10, key companies, important trends, and where you can go to learn more. …
While Saudi Arabia is becoming an increasingly attractive investment destination for global pharma, some stakeholders continue to have concerns about whether the country’s intellectual property (IP) protection system is truly…
Seasoned executive Mohamed Nasser currently oversees 16 markets for Amgen across the MEA region, including its most important – Saudi Arabia. He shares some of the key skills that pharma…
Saudi Chemical Company Holding (SCCH), Saudi Arabia’s leading manufacturer of civil and military explosives, has been expanding its pharma sector footprint in recent years. Today, the company has capabilities across…
The Saudi medtech market was valued at USD 2.25 billion in 2017 and is expected to reach USD 3.87 billion at a CAGR of 9.5 percent by 2023, according to…
With advances in technology, an increasing number of stable peptide-based therapeutics are being brought to market today across a wide range of therapeutic areas. Through expert insight, we explain why…
Speaking recently to PharmaBoardoom, Assobiotec’s Leonardo Vingiani introduced the key dynamics shaping the Italian biotech industry today and the issues it still has to overcome to become truly globally competitive.…
A rundown of five things to know about the healthcare and life sciences industry in Catalonia. Nestled in Northeastern Spain and bordering France, Catalonia’s capital and largest city is Barcelona.…
Europe lags behind the US in terms of biotech success stories, but one company bucking that trend is Denmark-headquartered Genmab, with a market cap of over USD 25 billion. Dual-listed…
The latest news from the Italian healthcare and life sciences industries, including the final piece in Angelini’s updated leadership team; the country’s digital health investment timetable; and the details of…
An overview of Italy's pharma, biotech and medtech sectors by number of companies, production value, R&D investment, and number of employees. Made with Visme Infographic Maker The Italian companies…
Speaking recently to PharmaBoardoom, Assobiotec’s Leonardo Vingiani introduced the key dynamics shaping the Italian biotech industry today and the issues it still has to overcome to become truly globally competitive.…
Based on IQVIA’s pharma market rankings for 2020, we give a rundown of the global top 10, key companies, important trends, and where you can go to learn more. …
One of the enduring conundrums around ground-breaking and potentially paradigm-shifting treatments such as CAR-T is the ever-thorny question of how fast to move them to market when the promise seems…
In recent years, the much-discussed concept of “patient centricity” has been top-of-mind across all corners of the pharma industry. This is especially pertinent now that many innovative drug makers are…
Marc Boutin, Novartis’ global head of patient engagement, outlines the company’s “bold vision” of patient engagement and the actions that need to be taken for CAR-T patients in the immediate,…
Chimeric antigen receptor (CAR-T) therapy was first approved by the US FDA back in 2017 amid a great deal of fanfare and high expectations among patients about its potential as…
A rundown of five things to know about the healthcare and life sciences industry in Catalonia. Nestled in Northeastern Spain and bordering France, Catalonia’s capital and largest city is Barcelona.…
The latest from Spanish pharma, including Rovi’s better-than-expected 2021 results thanks to its Moderna partnership, the approval of Hipra’s COVID-19 IIb clinical trials, Sanifit Therapeutics’ acquisition by Vifor Pharma, and…
Based on IQVIA’s pharma market rankings for 2020, we give a rundown of the global top 10, key companies, important trends, and where you can go to learn more. …
Aiming to leverage European Union funds to reindustrialise its economy, the Spanish government has approved a public-private collaboration instrument to transform its health sector. The project looks to position Spain…
The phenomenal success of the Pfizer/BioNTech and Moderna COVID-19 vaccines has catapulted messenger RNA (mRNA) vaccines into public consciousness, and mRNA technology is today receiving more scientific and financial attention…
Saudi Arabia’s response to COVID-19 stands up well to international comparisons in both the MENA region and globally. In recent conversation with PharmaBoardroom, Fahad Al Shebel, CEO of national medicine…
The latest news from Chinese pharma, including an examination of the new national reimbursement drug list (NRDL), the therapies that have and have not made it onto the list, and…
PPC China’s Sophia Duan, writing in the January edition of DIA’s Global Forum magazine, details how the emergence of an effective pharmacovigilance ecosystem is helping to safeguard the rollout of…
See our Cookie Privacy Policy Here